Resources

A collection of weekly infographics that provide a traffic light report of the coronavirus (COVID-19) situation across Australia.

This infographic issued on 27 January 2023 provides a weekly traffic light report of the coronavirus (COVID-19) situation across Australia.

A collection of resources for health professionals to help people with Gaucher disease (type 1) access the following drugs under the Life Saving Drugs Program: imiglucerase (Cerezyme®), velaglucerase (VPRIV®), and taliglucerase (Elelyso®).

A collection of resources for health professionals to help people with mucopolysaccharidosis type II (MPS II) access idursulfase (Elaprase®) under the Life Saving Drugs Program.

A collection of resources for health professionals to help people with Pompe disease access alglucosidase alfa (Myozyme®) and avalglucosidase alfa (Nexviazyme®) under the Life Saving Drugs Program.

This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This Gaucher disease review considered 3 enzyme replacement therapies (ERTs), imiglucerase, velaglucerase and taliglucerase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health.

This Gaucher disease review considered three enzyme replacement therapies (ERTs), imiglucerase, velaglucerase and taliglucerase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This user guide explains to administrators how to use the My Aged Care service and support portal.

This document outlines the terms of use for the Government Provider Management System (GPMS). The GPMS allows aged care service providers to see their Star Ratings.

Fact sheets and other health, aged care and sport information from the October 2022–23 Budget.

The residential aged care residents COVID-19 vaccination rates provides data by facility across Australia and is updated every Wednesday.

A list of National Health and Medical Research Council (NHMRC) projects and the committed funding.

Evaluation of the COAG Section 19(2) Exemptions Initiative – Improving Access to Primary Care in Rural and Remote Areas Final Report

This chart shows the structure of the Department of Health and Aged Care, including our divisions, branches, statutory office holders and high priority taskforces.

The National Aged Care Advisory Council list of monthly communiques.

The meeting of the National Aged Care Advisory Council was held on 15 December 2022.

An update from the Council of Elders after their meeting on 8 and 9 December, 2022.

Communiques from the Council of Elders.

Information and advice for general practitioners and other medical practitioners about the COVID-19 MBS telehealth ‘established relationship’ requirement, including a clarification of exemptions.